A detailed history of Bank Of America Corp transactions in Evolus, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 149,231 shares of EOLS stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
149,231
Previous 70,853 110.62%
Holding current value
$1.62 Million
Previous $768,000 214.71%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.66 - $17.48 $835,509 - $1.37 Million
78,378 Added 110.62%
149,231 $2.42 Million
Q2 2024

Aug 14, 2024

SELL
$10.45 - $13.76 $236,702 - $311,677
-22,651 Reduced 24.22%
70,853 $768,000
Q1 2024

May 15, 2024

BUY
$9.99 - $14.91 $119,730 - $178,696
11,985 Added 14.7%
93,504 $1.31 Million
Q4 2023

Feb 14, 2024

BUY
$7.6 - $10.53 $317,474 - $439,869
41,773 Added 105.1%
81,519 $858,000
Q2 2023

Aug 14, 2023

SELL
$7.23 - $10.52 $22,817 - $33,201
-3,156 Reduced 7.36%
39,746 $288,000
Q1 2023

May 12, 2023

BUY
$7.81 - $11.05 $25,515 - $36,100
3,267 Added 8.24%
42,902 $362,000
Q4 2022

Feb 10, 2023

SELL
$6.52 - $8.95 $81,708 - $112,161
-12,532 Reduced 24.02%
39,635 $297,000
Q3 2022

Nov 14, 2022

BUY
$7.76 - $13.72 $251,237 - $444,198
32,376 Added 163.59%
52,167 $420,000
Q2 2022

Aug 12, 2022

SELL
$10.22 - $13.94 $89,445 - $122,002
-8,752 Reduced 30.66%
19,791 $229,000
Q1 2022

May 16, 2022

SELL
$5.22 - $11.78 $2,014 - $4,547
-386 Reduced 1.33%
28,543 $320,000
Q4 2021

Feb 08, 2022

BUY
$5.37 - $8.38 $57,507 - $89,741
10,709 Added 58.78%
28,929 $189,000
Q3 2021

Nov 15, 2021

SELL
$7.36 - $13.67 $131,795 - $244,788
-17,907 Reduced 49.57%
18,220 $138,000
Q2 2021

Sep 13, 2021

BUY
$8.42 - $13.96 $304,189 - $504,332
36,127 New
36,127 $457,000

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $608M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.